ReviewFrontiers in oncology2026

Integrating new and "old" cellular therapies in the evolving landscape of relapsed or refractory large B-cell lymphoma.

Enrico Amaducci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.